Antimicrobial chemotherapy stands on the edge of a number of epoch-making discoveries. The British Society for Antimicrobial Chemotherapy’s ambition is to be in the vanguard of those discoveries.
To mark the anniversary of the Society’s first 50 years, we are inviting world-leading experts to speculate on what developments are likely to transform their field of work in the decades ahead. We want this report to prove thought-provoking, if not pathfinding – with recommendations helping to shape the future of our global community of infection specialists, as well as the future of the Society itself: its mission, the make-up of its Council and membership, the themes of future conferences and events, partnerships, the criteria for grant-making, and the nature of its interaction with the public, policymakers, and mainstream media.
We’ll publish articles on a different topic every month throughout 2021, before bringing them together at the end of the year in the form of a report with recommendations.
In the first article, Dr Michael T. Osterholm, director of the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota and, most recently, a member of President-elect Joe Biden’s Transition COVID-19 Advisory Board, describes how we can all become advocates for a new and better future, in spite of the increasingly complex threat of antimicrobial resistance.